Incyte | Gastos De Venta Y Administración



Selling And Administration Expenses Cambio Fecha
Acadia Pharmaceuticals USD 123.66M 2.71M 2025-06
Agios Pharmaceuticals USD 45.87M 4.34M 2025-06
Alnylam Pharmaceuticals USD 323.31M 83.36M 2025-06
Amgen USD 1.69B 4M 2025-06
Biogen USD 583.8M 11.3M 2025-06
BioMarin Pharmaceutical USD 232.28M 26.16M 2025-06
Bristol-Myers Squibb USD 1.71B 129M 2025-06
Eli Lilly USD 2.75B 390.8M 2025-06
Exelixis USD 134.86M 2.32M 2025-07
Gilead Sciences USD 1.36B 100M 2025-06
Incyte USD 331.02M 5.33M 2025-06
Ionis Pharmaceuticals USD 90.6M 14.6M 2025-06
MacroGenics USD 27.81M 13.71M 2024-12
Merck USD 2.63B 104M 2025-06
Moderna USD 230M 18M 2025-06
Neurocrine Biosciences USD 286.3M 9.8M 2025-06
Novartis USD 3.44B 384M 2025-06
Novartis USD 3.5B 368M 2024-12
Pfizer USD 3.42B 406M 2025-06
PTC Therapeutics USD 85.26M 76.66M 2025-06
Regeneron Pharmaceuticals USD 634.2M 1.2M 2025-06
Sarepta Therapeutics USD 69.89M 63.74M 2025-06
Ultragenyx Pharmaceutical USD 86.65M 1.15M 2025-06
Vertex Pharmaceuticals USD 424.6M 28.2M 2025-06


Incyte Gastos De Venta Y Administración - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Aug 2025.